hSSTR2 expression and octreotide treatment reverses multidrug resistance of BxPC-3 human pancreatic cancer cells

  • Authors:
    • Chenguang Sui
    • Qingyong Ma
    • Kejun Nan
    • Juxiang Xiao
    • Aili Suo
    • Huanchen Sha
    • Lei Zhao
  • View Affiliations

  • Published online on: December 1, 2009     https://doi.org/10.3892/or_00000579
  • Pages: 1391-1396
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Pancreatic cancer is generally refractory to most chemotherapeutic agents. We investigated whether hSSTR2 expression and octreotide treatment reverse multidrug resistance of human pancreatic cancer cells. We used pancreatic cancer cells that were transfected by using a lentivirus expression system, which allowed stable expression of the hSSTR2 gene in the pancreatic cancer cells. BxPC-3 cells were transfected with hSSTR2 through a lentivirus vector pWP XL-MOD-SSTR2 in order to enable the expression of hSSTR2. The transfected cells were treated with different concentrations of octreotide and with the chemotherapeutic agents cisplatin, epirubicin, fluorouracil and gemcitabine. The changes in IC50 following treatment with chemotherapeutic agents were determined, and the expression of different MDR indicating marker genes, multidrug resistance gene-1 (MDR1), multidrug resistance-associated protein 2 (MRP2), and lung resistance-related protein (LRP), were evaluated. Octreotide treatment of the transfected cells significantly decreased the IC50 of chemotherapeutic agents in a dose-dependent manner. hSSTR2 gene transfection decreased MDR1, MRP2 and LRP expression by 57, 47 and 56%, respectively (P<0.01), and octreotide treatment (1.6 µg/ml) for 48 h, decreased it further by 88, 73 and 87<, respectively (P<0.01). These data suggested that the down-regulation of MDR genes is responsible for the improvement in the chemotherapeutic sensitivity of hSSTR2-expressing pancreatic cancer cells, when these cells are subjected to octreotide treatment.

Related Articles

Journal Cover

December 2009
Volume 22 Issue 6

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Sui C, Ma Q, Nan K, Xiao J, Suo A, Sha H and Zhao L: hSSTR2 expression and octreotide treatment reverses multidrug resistance of BxPC-3 human pancreatic cancer cells . Oncol Rep 22: 1391-1396, 2009.
APA
Sui, C., Ma, Q., Nan, K., Xiao, J., Suo, A., Sha, H., & Zhao, L. (2009). hSSTR2 expression and octreotide treatment reverses multidrug resistance of BxPC-3 human pancreatic cancer cells . Oncology Reports, 22, 1391-1396. https://doi.org/10.3892/or_00000579
MLA
Sui, C., Ma, Q., Nan, K., Xiao, J., Suo, A., Sha, H., Zhao, L."hSSTR2 expression and octreotide treatment reverses multidrug resistance of BxPC-3 human pancreatic cancer cells ". Oncology Reports 22.6 (2009): 1391-1396.
Chicago
Sui, C., Ma, Q., Nan, K., Xiao, J., Suo, A., Sha, H., Zhao, L."hSSTR2 expression and octreotide treatment reverses multidrug resistance of BxPC-3 human pancreatic cancer cells ". Oncology Reports 22, no. 6 (2009): 1391-1396. https://doi.org/10.3892/or_00000579